Year: 2025

Press contactFahd PashaTel.: +1 647 860 3777Fahd.Pasha@capgemini.com Banks and insurers deploy AI agents to fight fraud and process applications, with plans for new roles to supervise the AIThree in five banks and insurers cite customer onboarding among top reasons for AI agent adoption 33% of firms are actively developing proprietary AI agents in-house, though only 10% have deployed at scale Nearly half of banks and insurers are creating new jobs to supervise AI agentsParis, November 12, 2025 – Financial institutions are actively moving key customer-facing processes to AI agents, marking a rapid transformation in how customers interact with banks and insurers. According to the Capgemini Research Institute’s World Cloud Report in Financial Services 2026, the top processes for banks to deploy cloud-native, AI agents at scale...

Hepsor AS (registry code 12099216, address Järvevena tee 7b, 10112, Tallinn, Estonia; Hepsor) announces a bond programme (Programme) in the total amount of EUR 20 million and a public offering (hereinafter Offer) of the first series of bonds under the Programme. As part of the offer, Hepsor will raise up to EUR 6 million, with the possibility of increasing the volume to EUR 8 million. The offer will be conducted on the basis of the main prospectus (hereinafter Prospectus) prepared by Hepsor and approved by the Estonian Financial Supervision Authority  on 10 November 2025, and published on the websites of Hepsor and the  Estonian Financial Supervision Authority on the date of this announcement. The Offer is intended for retail and institutional investors operating in Estonia, Latvia, and Lithuania. The main conditions of the OfferIssuer Hepsor...

Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 YearsCompany remains on track for VITESSE topline data in Q4 of this yearDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the last patient visit has been completed in the Company’s Phase 3 VITESSE clinical trial of the VIASKIN® Peanut patch in peanut allergic children aged 4-7 years. With the completion of the double-blind, placebo-controlled treatment phase of the study, DBV remains on track to announce topline data from VITESSE in the fourth quarter of this year. “Last patient last visit represents a very important milestone for...

PERTH, Australia, Nov. 11, 2025 (GLOBE NEWSWIRE) — Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce that it has released an updated corporate presentation for investors. The refreshed presentation provides the latest information on Novo’s exploration and development activities across its key gold projects in Australia, including recent drilling results, strategic priorities, and upcoming milestones for 2025. The updated investor presentation is available on the Company’s website at www.novoresources.com under the Investors and Media section. Novo Resources remains committed to delivering value to shareholders through focused exploration, strategic project advancement, and responsible resource development. Authorised for release by the Board of Directors. CONTACTInvestors:Mike...

The parametric insurance will protect livelihoods of 14,200 small-scale fishers, the first of its kind in the country SINGAPORE, Nov. 11, 2025 (GLOBE NEWSWIRE) — The Government of the Philippines, through the Bureau of Fisheries and Aquatic Resources (BFAR) and the Philippine Crop Insurance Corporation (PCIC), has partnered with global conservation organization Rare and Willis, a WTW business (NASDAQ: WTW), to launch the country’s first parametric insurance solution for small-scale fishers. This project has been developed through support from the Ocean Risk and Resilience Action Alliance (ORRAA) with funding from the Government of Canada and the UK Government’s Blue Planet Fund. The partnership is aimed at protecting the livelihoods of 14,200 small-scale fishers, across 24 coastal municipalities in the Philippines through parametric...

WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 9,677,420 shares of its common stock at a public offering price of $31.00 per share (such offering, the “Equity Offering”) and its underwritten public offering of $200.0 million aggregate principal amount of its 1.625% convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”). The Equity Offering was upsized from the previously announced offering size of $200.0 million of shares of common stock. Cogent estimates that the net proceeds from the Equity Offering and the Convertible...

SHANGHAI and NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) — TH International Limited (“Tims China” (Nasdaq: THCH)), the exclusive operator of Tim Hortons coffee shops in China, plans to release its third quarter financial results before the U.S. market opens on Tuesday, December 9, 2025, with a conference call to follow at 8:00 AM EST or 9:00 PM China Standard Time. The conference call will be webcast, and can be accessed on the company Investor Relations website at https://ir.timschina.com/events-presentations/presentations-webcasts. Participants are kindly encouraged to pre-register for the conference call, by using the link provided below. Pre-registration Link: https://register-conf.media-server.com/register/BId10b556eeb90481aa578a2eaa12a8b1e ABOUT TH INTERNATIONAL LIMITED TH International Limited (Nasdaq: THCH) (“Tims China”)...